Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Glioblastomas are the most common and lethal neoplasms of the central nervous system. Neighbouring glioma cells maintain extreme degrees of genetic and phenotypic variation that form intratumoural heterogeneity. This genetic diversity allows the most adaptive tumour clones to develop treatment resistance, ultimately leading to disease recurrence. We aimed to model this phenomenon and test the effectiveness of several targeted therapeutic interventions to overcome therapy resistance. Heterogeneous tumour masses were first deconstructed into single tumour cells, which were expanded independently as single-cell clones. Single nucleotide polymorphism arrays, whole-genome and RNA sequencing, and CpG methylation analysis validated the unique molecular profile of each tumour clone, which displayed distinct pathologic features, including cell morphology, growth rate, and resistance to temozolomide and ionizing radiation. We also identified variable sensitivities to AURK, CDK, and EGFR inhibitors which were consistent with the heterogeneous molecular alterations that each clone harboured. These targeted therapies effectively eliminated the temozolomide- and/or irradiation-resistant clones and also parental polyclonal cells. Our findings indicate that polyclonal tumours create a dynamic environment that consists of diverse tumour elements and treatment responses. Designing targeted therapies based on a range of molecular profiles can be a more effective strategy to eradicate treatment resistance, recurrence, and metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In glioblastoma, single-cell-derived subclones showed variable sensitivity to targeted therapies, and combination therapy with AURK, CDK, and EGFR inhibitors effectively eliminated resistant subclones (Akgül et al., 2019).”
From Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review (2026) · cites this paper as Akgül et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“net) and BAM files were coordinatesorted using Samtools [33].”
MethodInfluentialRobinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · cited 1×
“Further analysis was carried out in R using the edgeR package [38] for normalization of the expression data used a library size correction for gene count by million reads mapped and the trimmed mean of M-values (TMM) method [39] to facilitate cross sample comparisons.”
MethodThe Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 2×
“Somatic Variant Calling Single nucleotide substitution variants were detected using a dual calling strategy using qSNP [34] and the GATK HaplotypeCaller [35].”
MethodRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876 · cited 1×
“Further analysis was carried out in R using the edgeR package [38] for normalization of the expression data used a library size correction for gene count by million reads mapped and the trimmed mean of M-values (TMM) method [39] to facilitate cross sample comparisons.”
MethodVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“RNAseq data was used to classify samples into glioblastoma molecular subtypes [4,17,18].”
MethodAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Thus, the classification of glioblastoma into different subgroups based on their molecular profiles has been suggested to simplify the complexity of the disease, and also facilitate personalised treatment strategies [8].”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“stemness), and proliferation capacity between individual tumour cells/clones isolated from the same tumour mass [11,12].”
BackgroundThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · cited 2×
“To identify key oncogenic signals that could be targeted in a rationalised manner, we further investigated the somatic mutation, copy number status, and gene expression of known glioblastoma-associated candidate genes and related oncogenic pathways [3].”
BackgroundGreaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · cited 3×
“This could in part be due to a lack of patient stratification to identify those patients who could benefit from particular therapies and also varying drug responses as a result of intratumoural heterogeneity [14,15].”
BackgroundPhillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737 · cited 1×
“Initial attempts to better understand glioblastoma intratumoural heterogeneity was undertaken on spatially distinct regions of a single tumour, and analysing these distinct tumour fragments revealed both unique and common copy number alterations in different fragments [10].”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 1×
“Structural variants were determined using qSV as previously described [36].”
MethodSelf-citationMutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362 · cited 1×
“Thousands of de novo mutations and novel oncogenic signatures observed in these TMZ-resistant clones suggest that tumours branch out into new molecular profiles and evolve into even more malignant states after treatment [16].”
BackgroundMesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Bhat, K. P. L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J. D., Goodman, L. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.001 · Cited by 1,102
Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025 · cited 2×
“This was most likely a cause of the serum-free culture conditions used, which select for a more de-differentiated stem cell-like population [21].”
BackgroundMethodPatnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · cited 1×
“Similarly, only a small percentage (~17%) of patients benefited from CDK4/6 inhibitor Abemaciclib in another clinical trial [31].”
BackgroundMosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., Akhavanfard, S., Cahill, D. P., Aldape, K. D., Betensky, R. A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.005 · Cited by 707 · cited 1×
“The heterogeneous but co-existing distribution of these EGFR, MET, and PDGFRA gene amplifications suggests that glioblastoma may undergo a dynamic evolution during tumour progression that creates diversity within a single mass [13].”
BackgroundMechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705 · cited 1×
“However, recent studies have also demonstrated that the reversal of only one or a few oncogenic pathways could cease tumour progression or even eliminate the tumour mass as a whole [25].”
BackgroundBrennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., & Holland, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 534 · cited 1×
“RNAseq data was used to classify samples into glioblastoma molecular subtypes [4,17,18].”
MethodGlioblastoma: From Molecular Pathology to Targeted Treatment
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130324 · Cited by 518
Cellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498 · cited 3×
“Intratumoural heterogeneity poses additional challenges, as current pathological and molecular diagnostics are based only on a small region of the tumour, which may not be representative of the tumour mass as a whole [9].”
BackgroundInfluentialDewhurst, S. M., McGranahan, N., Burrell, R. A., Rowan, A. J., Grönroos, E., Endesfelder, D., Joshi, T., Mouradov, D., Gibbs, P., Ward, R. L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0285 · Cited by 449 · cited 1×
“Nevertheless, WGD in cancer has a suggested role in increasing tolerance to chromosome instability and genomic evolution [29], which may accelerate intratumoral heterogeneity.”
BackgroundOncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441 · cited 1×
“This phenomenon, described as oncogene addiction, is a characteristic whereby tumour cells become dependent on a single oncogenic pathway in order to survive [26,27].”
BackgroundMcCartney, D. L., Walker, R. M., Morris, S. W., McIntosh, A. M., Porteous, D. J., & Evans, K. L. (2016) · Genomics Data · doi:10.1016/j.gdata.2016.05.012 · Cited by 388
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M., Bayani, J., Pressey, J. C., Lionel, A. C., Clarke, I. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320611111 · Cited by 382
Xie, Y., Bergström, T., Jiang, Y., Johansson, P., Marinescu, V. D., Lindberg, N., Segerman, A., Wicher, G., Niklasson, M., Baskaran, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.026 · Cited by 333
Reardon, D. A., Nabors, L. B., Mason, W. P., Perry, J. R., Shapiro, W., Kavan, P., Mathieu, D., Phuphanich, S., Cseh, A., Fu, Y., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou160 · Cited by 189 · cited 1×
“This finding may provide some explanation for the limited efficacy of Afatinib as a single agent in unselected patients with recurrent glioblastoma [30].”
Hallmarks of glioblastoma: a systematic review
Nørøxe, D. S., Poulsen, H. S., & Lassen, U. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000144 · Cited by 183 · cited 1×
“The overall and progression-free survival has not changed since the introduction of concomitant and adjuvant radiotherapy and chemotherapy in the form of temozolomide (TMZ) in 2005 [1,2].”
BackgroundascatNgs: Identifying Somatically Acquired Copy‐Number Alterations from Whole‐Genome Sequencing Data
Raine, K. M., Van Loo, P., Wedge, D. C., Jones, D., Menzies, A., Butler, A. P., Teague, J. W., Tarpey, P., Nik‐Zainal, S., & Campbell, P. J. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.17 · Cited by 170 · cited 1×
“The copy number was determined using sequencing data and the tool ascatNGS [37].”
MethodSINGLE CELL DERIVED CLONAL ANALYSIS OF HUMAN GLIOBLASTOMA LINKS FUNCTIONAL AND GENOMIC HETEROGENEITY
Dirks, P. B., Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M., Bayani, J., Pressey, J. C., Lionel, A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.51 · Cited by 132
Current clinical development of PI3K pathway inhibitors in glioblastoma
Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L., & Alfred Yung, W. K. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos117 · Cited by 130 · cited 1×
“For instance, targeting the PI3K/AKT pathway alone or in combination with radiotherapy led to either varying or short-lived responses [28].”
BackgroundGlioblastoma: Molecular Analysis and Clinical Implications
Huse, J. T., Holland, E., & DeAngelis, L. M. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-100711-143028 · Cited by 97 · cited 2×
“These alterations lead to deregulation in various genes and networks, allowing tumours to become more malignant and resistant to therapy [23,24].”
BackgroundSomatic Point Mutation Calling in Low Cellularity Tumors
Kassahn, K. S., Holmes, O., Nones, K., Patch, A.-M., Miller, D. K., Christ, A. N., Harliwong, I., Bruxner, T. J., Xu, Q., Anderson, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074380 · Cited by 81
Self-citationGlioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research
Day, B. W., Stringer, B. W., Wilson, J., Jeffree, R. L., Jamieson, P. R., Ensbey, K. S., Bruce, Z. C., Inglis, P., Allan, S., Winter, C. D., et al. (2013) · Cancers · doi:10.3390/cancers5020357 · Cited by 70 · cited 1×
“We have developed a characterised glioblastoma patient-derived cell line resource (Q-Cell) [32], in which glioblastoma lines are maintained as glioma neural stem cell (GNS) cultures [21] or as”
MethodSelf-citationAkgül, S., Li, Y., Zheng, S., Kool, M., Treisman, D. M., Li, C., Wang, Y., Gröbner, S. N., Ikenoue, T., Shen, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.050 · Cited by 51
Self-citation
Cited by
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
“The researchers found that, at recurrence, most tumors maintained the clonal structure of the original tumor and that selective pressures occurred mostly early in gliomagenesis rather than as a result of treatment [58,59].”
BackgroundTumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
Becker, A., Sells, B., Haque, S., & Chakravarti, A. (2021) · Cancers · doi:10.3390/cancers13040761 · Cited by 212
“through bar coding techniques enabled the evaluation of gene expression at single cell level [56,62,66,67].”
BackgroundInfluentialCancer Stem Cell Plasticity – A Deadly Deal
Thankamony, A. P., Saxena, K., Murali, R., Jolly, M. K., & Nair, R. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00079 · Cited by 171
Zhang, Q., & Liu, F. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2696-5 · Cited by 148
In Vitro Glioblastoma Models: A Journey into the Third Dimension
Paolillo, M., Comincini, S., & Schinelli, S. (2021) · Cancers · doi:10.3390/cancers13102449 · Cited by 90
“The genetic diversity is an ef‐ fective way that GBM cells inside the tumor mass use to develop treatment resistance, a selection process that in turn supports the most typical and deadly factor in GBM malig‐ nity: disease recurrence [81].”
Background
Metadata
- Authors
- Akgül, S., Patch, A.-M., D’Souza, R. C. J., Mukhopadhyay, P., Nones, K., Kempe, S., Kazakoff, S. H., Jeffree, R. L., Stringer, B. W., Pearson, J. V., Waddell, N., & Day, B. W.
- Affiliations
- Griffith University (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia
- Royal Brisbane and Women's Hospital (AU)
- Queensland University of Technology (AU)
- Corresponding author
- Day, Bryan W.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-02-06
- Volume
- 11
- Issue
- 2
- Pages
- 190
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6406894
- OpenAlex
- W2913741278
- Cited by
- 57
- References
- 41
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 16 · 2020: 11 · 2019: 6
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Health and Medical Research Council (1139071)
- Sid Faithfull Group (*)
- Cure Brain Cancer Foundation (*)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, intratumoral heterogeneity, treatment resistance, temozolomide resistance, radioresistance (biology), targeted therapy, cyclin-dependent kinase inhibitors, EGFR inhibitors, tumor recurrence, epigenetic heterogeneity, CpG methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.